Specifically, A3 virus carrying the TRAIL gene more effectively inhibited cell growth compared to CRAd5 with no therapeutic genes, indicating that TRAIL-mediated gene therapy is effective in glioma cells; TRAIL modification on pIX also improved the anti-tumor efficiency (A4 vs. A3). The gene discussed is TNFSF10; the disease is neoplasm.